[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Yamada et al., 2014 - Google Patents

Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates

Yamada et al., 2014

View HTML @Full View
Document ID
9351922237800569736
Author
Yamada Y
Ochiai T
Boskovic S
Nadazdin O
Oura T
Schoenfeld D
Cappetta K
Smith R
Colvin R
Madsen J
Sachs D
Benichou G
Cosimi A
Kawai T
Publication year
Publication venue
American Journal of Transplantation

External Links

Snippet

We have previously reported successful induction of renal allograft tolerance via a mixed chimerism approach in nonhuman primates. In those studies, we found that costimulatory blockade with anti-CD154 mAb was an effective adjunctive therapy for induction of renal …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Similar Documents

Publication Publication Date Title
Yamada et al. Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates
Matthews et al. Clinical trials of transplant tolerance: slow but steady progress
Lechler et al. Organ transplantation—how much of the promise has been realized?
Wekerle et al. Belatacept: from rational design to clinical application
Ford et al. Translating costimulation blockade to the clinic: lessons learned from three pathways
Wekerle et al. ANTI-CD154 OR CTLA4Ig OBVIATES THE NEED FOR THYMIC IRRADIATION IN A NON-MYELOABLATIVE CONDITIONING REGIMEN FOR THE INDUCTION OF MIXED HEMATOPOIETIC CHIMERISM AND TOLERANCE1
Thompson et al. Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival
Poirier et al. Inducing CTLA-4–dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation
US6514513B1 (en) Costimulatory blockade and mixed chimerism in transplantation
Sasaki et al. Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach
US20120269806A1 (en) Methods of inducing tolerance
CN101198347A (en) Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
Lee et al. Alefacept promotes immunosuppression‐free renal allograft survival in nonhuman primates via depletion of recipient memory T cells
Rickert et al. Current state of organ transplant tolerance
US20240270845A1 (en) Anti-cd2 antibodies
Poirier et al. A more selective costimulatory blockade of the CD28‐B7 pathway
Knechtle et al. Tolerance and near‐tolerance strategies in monkeys and their application to human renal transplantation
US20210268023A1 (en) Enhanced CAR Tregs and Bi-Specific Antibodies for Induction of Immune Tolerance, Treating Autoimmune Diseases and Preventing Transplantation Rejection
Giannis et al. Costimulation blockade in vascularized composite allotransplantation
Guo et al. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic NOD mice from autoimmune destruction and allogeneic and xenogeneic graft rejection1
Uehara et al. The role of costimulatory pathways in transplant tolerance
Guo et al. Long‐term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion
Vanhove et al. Selective costimulation blockade with antagonist anti-CD28 therapeutics in transplantation
Snanoudj et al. Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits
Snanoudj et al. The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept